tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hyperlipidemias D006949 73 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Hypersensitivity D006967 22 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Hypertension D006973 115 associated lipids
Hypertension, Portal D006975 12 associated lipids
Hypertension, Renal D006977 9 associated lipids
Hypoglycemia D007003 13 associated lipids
Hypotension D007022 41 associated lipids
Hypothermia D007035 19 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Immune System Diseases D007154 3 associated lipids
Impetigo D007169 3 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Infection D007239 6 associated lipids
Inflammation D007249 119 associated lipids
Influenza, Human D007251 11 associated lipids
Insulin Resistance D007333 99 associated lipids
Intertrigo D007402 1 associated lipids
Intestinal Atresia D007409 3 associated lipids
Intestinal Fistula D007412 1 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Intussusception D007443 1 associated lipids
Ischemia D007511 18 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Keloid D007627 12 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Labyrinthitis D007762 2 associated lipids
Leg Injuries D007869 2 associated lipids
Legionellosis D007876 3 associated lipids
Lentigo D007911 1 associated lipids
Leukemia D007938 74 associated lipids
Leukemia P388 D007941 43 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Leukocytosis D007964 9 associated lipids
Leukoplakia D007971 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Lichen Planus D008010 3 associated lipids
Listeriosis D008088 12 associated lipids
Liver Abscess D008100 6 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Liver Diseases D008107 31 associated lipids
Long QT Syndrome D008133 10 associated lipids
Lung Abscess D008169 1 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lupus Nephritis D008181 8 associated lipids
Lymphocele D008210 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Lymphoma D008223 18 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Malacoplakia D008287 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Mastocytosis D008415 5 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Mediastinitis D008480 2 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Melanoma D008545 69 associated lipids
Memory Disorders D008569 33 associated lipids
Meningococcal Infections D008589 3 associated lipids
Meningoencephalitis D008590 4 associated lipids
Metaplasia D008679 7 associated lipids
Mite Infestations D008924 1 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Mouth Diseases D009059 5 associated lipids
Moyamoya Disease D009072 1 associated lipids
Multiple Myeloma D009101 13 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Mutism D009155 1 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Mycoses D009181 18 associated lipids
Myelitis D009187 1 associated lipids
Myxedema D009230 2 associated lipids
Nail Diseases D009260 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nephritis D009393 19 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Meiser BM et al. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. 1991 Lancet pmid:1719321
Moochhala SM et al. Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721277
Katz HR et al. Mast cell biochemical and functional heterogeneity. 1991 Transplant. Proc. pmid:1721308
de Paulis A et al. Antiinflammatory effect of FK 506 on human basophils. 1991 Transplant. Proc. pmid:1721309
Reding R et al. Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. 1991 Transplant. Proc. pmid:1721341
Fung JJ et al. Adverse effects associated with the use of FK 506. 1991 Transplant. Proc. pmid:1721372
Omar G et al. FK 506 inhibition of cyclosporine metabolism by human liver microsomes. 1991 Transplant. Proc. pmid:1703356
Hebert MF et al. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. 1991 Transplant. Proc. pmid:1721373
Eiras G et al. Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. 1991 Transplant. Proc. pmid:1703357
de Bruin RW et al. Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721429
Iwaki Y et al. Replacement of donor lymphoid tissue in small-bowel transplants. 1991 Lancet pmid:1707470
Langrehr JM et al. FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. 1991 Transplant. Proc. pmid:1721430
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Bolton C The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. 1991 Transplant. Proc. pmid:1721462
Altmeyer A et al. Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. 1991 Int. J. Immunopharmacol. pmid:1726093
Gordon RD et al. Liver transplantation at the University of Pittsburgh, 1984 to 1990. 1991 Clin Transpl pmid:1726458
Morris RE et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. 1991 Transplant. Proc. pmid:1703698
Gailliot FP et al. Fluidized bed adsorption for whole broth extraction. 1990 Sep-Oct Biotechnol. Prog. pmid:1366874
Naouri A and Tissot E [Indications for liver transplantation in adults]. 1990 Jun-Jul J Chir (Paris) pmid:1698800
MacLeod AM and Thomson AW [FK-506. A new immunosuppressive drug]. 1990 Jul-Sep Medicina (Firenze) pmid:1706817
Wasik M et al. Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. 1990 Jul-Aug Immunopharmacology pmid:1699911
Dumont FJ et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. 1990 J. Immunol. pmid:1688572
Woo J et al. Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. 1990 Clin. Exp. Immunol. pmid:1689226
Dumont FJ et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. 1990 J. Immunol. pmid:1689353
Monden M et al. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. 1990 Transplant. Proc. pmid:1689904
Ericzon BG et al. Pancreaticoduodenal allotransplantation with FK 506 in the cynomolgus monkey. 1990 Transplant. Proc. pmid:1689905
Murase N et al. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. 1990 Transplant. Proc. pmid:1689906
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Nalesnik MA et al. The effect of FK 506 and CyA on the Lewis rat renal ischemia model. 1990 Transplant. Proc. pmid:1689911
Francavilla A et al. FK 506 as a growth control factor. 1990 Transplant. Proc. pmid:1689912
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
Standaert RF et al. Molecular cloning and overexpression of the human FK506-binding protein FKBP. 1990 Nature pmid:1696686
Tropschug M et al. Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. 1990 Nature pmid:1696687
Randall T New antirejection drugs anticipated. 1990 JAMA pmid:1696999
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Woo J et al. Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. 1990 Transplant. Proc. pmid:1697113
Takai K et al. Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. 1990 Clin. Exp. Immunol. pmid:1702372
Okubo Y et al. FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. 1990 Clin. Exp. Immunol. pmid:1702373
Arita C et al. Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. 1990 Clin. Exp. Immunol. pmid:1702374
Woo J et al. Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. 1990 Clin. Exp. Immunol. pmid:1702375
Mattila PS et al. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. 1990 EMBO J. pmid:1702384
Kawashima H et al. Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. 1990 Invest. Ophthalmol. Vis. Sci. pmid:1702408
Wilkinson PC and Watson EA FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. 1990 Immunology pmid:1702750
Metcalfe S and Milner J Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. 1990 Immunol. Lett. pmid:1702753
Takada K et al. Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. 1990 J. Chromatogr. pmid:1703552